A Phase 3 interventional study of TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 27 sites in 9 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-02-11.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 33rd largest by enrollment, is one of 5 that started in 2018, is one of 25 in phase 3, and was the 20th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 5 started in 2018.
This study's enrollment of 67 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 65th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2018, is one of 62 in phase 3, and was the 78th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of tezacaftor in combination with ivacaftor (TEZ/IVA) in participants with cystic fibrosis (CF) aged 6 through 11 years, who are homozygous for the F508del mutation (F/F) or heterozygous for F508del with an eligible residual function mutation (F/RF).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with genotype F/F received placebo matched to TEZ/IVA fixed dose combination (FDC) in the morning and placebo matched to IVA in the evening for 8 weeks.
Drug: Placebo
Participants with genotype F/F received TEZ/IVA FDC in the morning and IVA in the evening for 8 weeks. Participants with genotype F/RF received TEZ/IVA FDC and placebo matched to IVA in the morning and IVA in the evening for 8 weeks.
Drug: TEZ/IVA · Drug: IVA · Drug: Placebo
Participants with genotype F/RF received placebo matched to TEZ/IVA FDC in the morning and IVA in morning and evening for 8 weeks.
Drug: IVA · Drug: Placebo
Drug pages: Tezacaftor · Ivacaftor
Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg FDC tablet and those weighing ≥40 kg received TEZ 100 mg/IVA 150 mg FDC tablet.
Also known as: VX-661/VX-770, tezacaftor/ivacaftor fixed dose combination
Participants weighing \<40 kg IVA 75 mg tablet and those weighing ≥40 kg received IVA 150 mg tablet.
Also known as: VX-770, ivacaftor
Placebo matched to TEZ/IVA FDC
Placebo matched to IVA
Absolute Change in Lung Clearance Index 2.5 (LCI2.5) Through Week 8
LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
Time frame: From baseline through Week 8
Absolute Change in Sweat Chloride At Week 8
Sweat samples were collected using an approved collection device.
Time frame: From baseline at Week 8
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 8
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: From baseline through Week 8
Safety and Tolerability as Assessed Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Safety Follow-up Visit
Time frame: From first dose of study drug up to safety follow-up visit (up to Week 12)
| Milestone | Placebo | TEZ/IVA | Ivacaftor |
|---|---|---|---|
| Started | 10 | 54 | 3 |
| Completed | 10 | 53 | 3 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
| lung clearance index | TEZ/IVA |
|---|---|
| Absolute Change in Lung Clearance Index 2.5 (LCI2.5) Through Week 8 | -0.51 ± 0.11 |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | TEZ/IVA |
|---|---|
| Absolute Change in Sweat Chloride At Week 8 | -12.3 ± 1.5 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | TEZ/IVA |
|---|---|
| Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 8 | 2.3 ± 1.2 |
| Participants | Placebo | TEZ/IVA | Ivacaftor |
|---|---|---|---|
| Participants with AEs | 8 | 41 | 2 |
| Participants with SAEs | 0 | 0 | 0 |
Collected over From first dose of study drug up to safety follow-up visit (up to Week 12). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| TEZ/IVA | 0/54 (0%) | 0/54 (0%) | 31/54 (57.4%) |
| Ivacaftor | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Event | Placebo | TEZ/IVA | Ivacaftor |
|---|---|---|---|
| Arthropod biteInjury, poisoning and procedural complications | 0/10 | 0/54 | 1/3 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/10 | 3/54 | 1/3 |
| BlisterSkin and subcutaneous tissue disorders | 0/10 | 0/54 | 1/3 |
| ImpetigoInfections and infestations | 0/10 | 0/54 | 1/3 |
| Upper respiratory tract infectionInfections and infestations | 0/10 | 0/54 | 1/3 |
| Viral upper respiratory tract infectionInfections and infestations | 0/10 | 0/54 | 1/3 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 2/10 | 3/54 | 0/3 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/10 | 9/54 | 0/3 |
| HeadacheNervous system disorders | 1/10 | 8/54 | 0/3 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 1/10 | 7/54 | 0/3 |
| Age, Continuous(years) | Placebo | TEZ/IVA | Ivacaftor | Total |
|---|---|---|---|---|
| Mean | 9.0 ± 1.7 | 8.5 ± 1.7 | 9.0 ± 1.7 | 8.6 ± 1.7 |
| Sex: Female, Male(Participants) | Placebo | TEZ/IVA | Ivacaftor | Total |
|---|---|---|---|---|
| Female | 6 | 29 | 2 | 37 |
| Male | 4 | 25 | 1 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | TEZ/IVA | Ivacaftor | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 10 | 46 | 3 | 59 |
| Unknown or Not Reported | 0 | 7 | 0 | 7 |
| Race (NIH/OMB)(Participants) | Placebo | TEZ/IVA | Ivacaftor | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 10 | 51 | 3 | 64 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 0 | 2 |
| Lung Clearance Index 2.5 (LCI2.5)(lung clearance index) | Placebo | TEZ/IVA | Ivacaftor | Total |
|---|---|---|---|---|
| Mean | 9.67 ± 1.65 | 9.56 ± 2.06 | 8.60 ± 1.40 | 9.54 ± 1.97 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Dec 2018, 7 months.
Results were first posted in Feb 2020, 1 year 1 month after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 7 months is below that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →